MedTrace Logo

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

NCT04951492 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2025-01-01

Study results available
· View outcomes & findings →

Summary

This phase II trial investigates the effect of olaparib in treating patients with castration resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma

Interventions

DRUG

Olaparib

Given PO

Sponsors & Collaborators

Principal Investigators

  • Michael Schweizer · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-09
Primary Completion
2023-10-15
Completion
2023-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04951492 on ClinicalTrials.gov